The Agenda: Back a little late….
Week of November 26:
In case anyone missed it, the New York Times Magazine ran an illuminating (and lengthy) piece by Daniel Carlat on his experience speaking to other doctors about Effexor XR for Wyeth Pharmaceuticals.
Also:
A major discovery in the stem cell space could mean challenges ahead for communicators (I’ve written about the need for communicators in the world of stem cell research before).
And a new poll takes a look at sales reps and their feelings towards the PhRMA guidlines (hint: they don’t like the code).
